GlycoMimetics E-selectin and Blood Cancer Data to Be Highlighted at 57th Annual ASH Meeting
A series of studies, selected for an oral presentation at ASH, demonstrated that GMI-1271 could be used to mobilize and enrich a population of primitive T cells known as T memory stem (Tscm) or T central memory (Tcm) cells. These Tscm/cm cells are known to have greater reconstitution and survival properties making them ideal for use in adoptive T-cell therapy, including engineered CAR-T approaches. GMI-1271, an antagonist to the cell adhesion molecule E-selectin, is currently being testing in patients with acute myeloid leukemia (AML) in a Phase 1/2 clinical study designed to evaluate its safety, pharmacokinetics (PK) and efficacy when used together with chemotherapy.
Safety, pharmacokinetic and biomarker profiles from a recently completed Phase 1 clinical trial of GMI-1271 in healthy volunteers will also be presented. In addition, data demonstrating that GMI-1271 can overcome drug resistance in animal models of multiple myeloma will be presented in an ASH poster.
For the first time, preclinical data on GMI-1359 antitumor activity in
hematologic malignancies will be presented publicly. Specifically, data
demonstrating that GMI-1359 synergizes with chemotherapy in animal
models of Flt-3 positive AML will be presented in a poster session. GMI-1359
is a compound that targets both E-selectin and CXCR4, established
pathways for cancer cell trafficking and resistance to chemotherapy.
"The fact that a total of four abstracts on GMI-1271 and GMI-1359 were
accepted for the ASH meeting, and that the latest data from our work is
being presented orally for the eighth year in a row at the meeting,
underscores the potential of these drug candidates as more effective
treatments for blood cancers like multiple myeloma and acute myeloid
leukemia. In addition, the data on mobilization and enrichment of
Tscm/cm cells demonstrates exciting possible applications of GMI-1271 in
cancer immunotherapy approaches," said
Details of the abstracts, including session times and locations, include:
Oral Presentation
"Mobilization of CD8+ Central Memory T-Cells with Enhanced
Reconstitution Potential in Mice By a Combination of G-CSF and
GMI-1271-Mediated E-Selectin Blockade." Abstract Submission #86643
(Session Name: 711. Cell Collection and Processing: Comparative Studies
and Novel Agents.)
Posters
"First in Human Phase 1 Single Dose Escalation Studies of the E-Selectin
Antagonist GMI-1271 Show a Favorable Safety, Pharmacokinetic, and
Biomarker Profile." Abstract Submission #84143 (Session Name: 201.
Granulocytes, Monocytes and Macrophages: Poster I.)
"The Dual E-Selectin/CXCR4 Inhibitor, GMI-1359, Enhances Efficacy of
Anti-Leukemia Chemotherapy in FLT3-ITD Mutated Acute Myeloid
Leukemia." Abstract Submission #86176 (Session Name: 616. Acute Myeloid
Leukemia: Novel Therapy, Excluding Transplantation: Poster III.)
"E-Selectin Ligand Expression Increases with Progression of Myeloma and
Induces Drug Resistance in a Murine Transplant Model, Which is Overcome
by the Glycomimetic E-Selectin Antagonist, GMI-1271." Abstract
Submission #85139 (Session Name: 652. Myeloma: Pathophysiology and
Pre-Clinical Studies, Excluding Therapy: Poster I.)
The meeting abstracts are available at ASH's website.
About
GlycoMimetics's wholly-owned drug candidate (GMI-1271) for AML and other
blood disorders is also in clinical trials.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements regarding the
clinical development of GMI-1271 and GMI-1359. Actual results may differ
materially from those in these forward-looking statements. For a further
description of the risks associated with these statements, as well as
other risks facing
View source version on businesswire.com: http://www.businesswire.com/news/home/20151109005870/en/
Investor Contact:
sannes@annesassociates.com
or
Media
Contact:
jamielacey@presscommpr.com
Source:
News Provided by Acquire Media